doi: 10.5732/cjc.013.10051

Molecular targeted agents—where we are and where we are going

Li Yan

Merck & Co., Inc., North Wales, PA 19454-1099, USA; US Chinese Anti-Cancer Association, Los Angeles, CA 90036, USA; School of Oncology, Peking University Cancer Hospital, Beijing Cancer Hospital, Beijing 100142, P. R. China.

[Abstract] A total of 23 new cancer medicines or indication expansions were approved by the U. S. Food and Drug Administration in 2012. Among these, 12 are new molecular entities (NMEs)—new chemical or biological drugs approved for the first time for oncologic use—and 10 of these NMEs are molecular targeted agents. Among the 10 targeted agents, 4 are anti-angiogenesis agents and 2 are Bcr-Abl pathway inhibitors, targeting well established targets validated by previously approved agents such as bevacizumab (Avastin) or imatinib (Gleevec). Despite this progress, several questions remain: Do these newly approved agents provide sufficient treatment options to manage the broad spectrum of cancers we deal with in the clinic? Where will the next wave of new cancer drugs come from? Where should R&D efforts be invested to continue improve cancer treatment and management, especially for tumor types uniquely prevalent in China? This editorial and the review articles in this special issue of Chinese Journal of Cancer provide an in depth review of the progress and challenges in developing targeted cancer therapies, as well as an outlook of new research areas where near term breakthroughs are expected to overcome some of these challenges.

Chinese Journal of Cancer 2013, Volume: 32, Issue 5, Page: 225-232

[ PDF Full-text ]
[ Html full-text ](PubMed Central)
[ PubMed ]
[Google Scholar]

Cite this article

Li Yan. Molecular targeted agents—where we are and where we are going. Chin J Cancer. 2013, 32(5):225-232. doi:10.5732/cjc.013.10051


Export citations

EndNote